Mechanism of effective vaccine invention by macrophages of apoptotic cells highly infected by SAR-CoV-2 Virus(Corona virus):-     


CSL chief scientific officer professor Andrew
Cuthbertson said: “CSL will contribute to UQ's
promising vaccine with our proprietary
adjuvant, MF59, made by Seqirus, along with
expertise in process science and scale-up
from our Australian facilities, managing
advanced clinical trials and the large-scale
manufacture of the recombinant vaccine.
“Should trials be successful, this vaccine holds
the potential to provide protection against this
urgent public health emergency for
Australians and those around the world
vulnerable to this devastating virus.”
CEPI partnered with UQ in January last year to
provide up to $10.6m to create a rapid
response “molecular clamp” vaccine platform.
The partnership was extended this January to
use the molecular clamp vaccine platform to
develop a Covid-19 vaccine candidate. UQ
plans to advance the vaccine candidate into a
Phase I clinical trial next month.The vaccine will be available in the begining of next year.